0.03
+0(+0.00%)
Currency In USD
Address
5 Nahum Heftsadie Street
Jerusalem, 91340
Israel
Phone
972 2 659 5666
Website
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
October 26, 2018
| Name | Title | Pay | Year Born |
| Ms. Abigail L. Jenkins | President, Chief Executive Officer & Director | 554,053 | 1976 |
| Mr. Joshua F. Patterson | General Counsel & Chief Compliance Officer | 479,000 | 1977 |
| Dr. Ronit Simantov M.D. | Chief Medical Officer & Chief Scientific Officer | 592,000 | 1965 |
| Ms. Michele Ilene Korfin M.B.A., R.Ph. | Chief Operating & Chief Commercial Officer | 606,000 | 1972 |
| Ms. Linda Stamler | Vice President of Marketing & Account Management | 0 | N/A |
| Mr. Naftali Brikashvili CPA | Senior Vice President Finance & Operations | 0 | N/A |
| Dr. Tracey Lodie Ph.D. | Scientific Advisor & Consultant | 0 | 1970 |
| Mr. Vladimir Melnikov | Senior Vice President of Global Operations & Manufacturing | 0 | N/A |
| Ms. Mary Theresa Coelho M.B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 0 | 1963 |
| Ms. Penny Bushell | Chief Human Resource Officer | 0 | N/A |
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.